Overview
Forge a new path to better lipid nanoparticle (LNP)-based gene therapies and vaccines with solutions for lipid structural elucidation that reach unprecedented depth and quantitation accuracy, precision and sensitivity.
Turn ionizable lipid N-oxidation, double-bond saturations and other lipid impurity challenges into opportunities. Join the team to rewrite the rules of lipid analysis with workflows looking beyond the known.
LNPs pose unique analytical challenges, in part due to the complexity of their lipid excipients. Consequently, the detailed structure elucidation capabilities afforded by electron activated dissociation (EAD) in the SCIEX ZenoTOF 7600 system provide the analytical chemist unparalleled capacity to identify problematic oxidative impurities inside ionizable lipids, and thereby de-risk the LNP therapeutic development process and expedite paths to the clinic.
Workflow
Lipid structural elucidation
Take your journey further with the ability to identify and quantify the lipid impurities present at well below 0.1% relative intensity.
Workflows with novel fragmentation mechanisms overcome the limitations of traditional techniques, allowing full structural assessment of lipids and their impurities from raw materials and LNPs. Customizable, automated and data-driven solutions for lipid structural elucidation let you break free from the boundaries of drug formulation development.
-
Fully understand the structures of your ionizable lipids and impurities
-
Identify different oxygen incorporations, including N-oxides, saturated double bonds and more
-
Reclaim your time with automatic processing of complex data
-
Find relevant product excipients using state-of-the-art mass spectrometry solutions
-
Benefit from simultaneous quantitation capabilities
Lipid structural elucidation
Solution
ExionLC AE system
ZenoTOF 7600 system
Molecule Profiler software
Featured resources
Break down frontiers of structural characterization of lipids and their impurities to develop better drugs. Dedicated solutions help your team confidently advance the next generation of therapies and vaccines.
Take control of lipid impurities! Learn how to save your team's time and resources by leveraging full solutions that enable you to break through the boundaries around the structural identification of lipids and their impurities.
Create pathways to know more about your non-viral carrier. Discover solutions that reliably identify process-related lipid impurities from raw material and LNPs.
Hear from expert Adam Crowe (Precision NanoSystems Inc., part of Cytiva) about lipid impurities, the associated risks and how to develop better LNP-based drugs.
To ensure the safety and efficacy of LNP-based drugs, comprehensive characterization of these sophisticated molecules—the lipids and the genetic cargo, such as messenger RNA (mRNA)—is paramount. This webinar explores the analytical challenges of characterizing mRNA-LNPs and a range of potential solutions.
Workflow
Lipid impurity quantitation
Take back your time with the ability to confirm and quantify hundreds of analytes in a streamlined manner.
Monitoring known lipid impurities and other critical components in lipid raw materials and LNPs is easier than ever before. Take control with intuitive, highly sensitive and reliable solutions.
-
Achieve highly sensitive analyte detection independently of ionization polarity
-
Easily obtain comprehensive results using intuitive data processing solutions
-
Be confident with compliance-ready solutions that are robust and reliable
Lipid impurity quantitation
Solution
- Monitoring of known lipid impurities
- Superior sensitivity and robustness
ExionLC AE system
SCIEX 7500 system
SCIEX OS software
All resources
Break through the boundaries of developing better LNP-based drugs. Take back your time with streamlined CE and MS workflows to learn more about your LNPs.
Break down frontiers of structural characterization of lipids and their impurities to develop better drugs. Dedicated solutions help your team confidently advance the next generation of therapies and vaccines.
Take control of lipid impurities! Learn how to save your team's time and resources by leveraging full solutions that enable you to break through the boundaries around the structural identification of lipids and their impurities.
Create pathways to know more about your non-viral carrier. Discover solutions that reliably identify process-related lipid impurities from raw material and LNPs.
Hear from expert Adam Crowe (Precision NanoSystems, ULC) about lipid impurities, the associated risk and how to develop better LNP-based drugs.
Set your own schedule by simultaneously monitoring lipids, using the robust and reliable quantitative data to continuously improve lipid-based delivery systems.
To ensure the safety and efficacy of LNP-based drugs, comprehensive characterization of these sophisticated molecules—the lipids and the genetic cargo, such as messenger RNA (mRNA)—is paramount. This webinar explores the analytical challenges of characterizing mRNA-LNPs and a range of potential solutions.
Associated applications
CRISPR/Cas9 analysis
Set your own schedule for CRISPR/Cas9 gene editing with innovative, intuitive analytical solutions. Unleash the potential of your Cas9 messenger RNA (mRNA), single guide RNA (sgRNA) and Cas9 proteins by understanding quality, purity and safety and assessing on/off target effects.
Messenger RNA analysis
Break through barriers and extend the frontiers of messenger RNA (mRNA), self-amplifying RNA (saRNA) and circular RNA (circRNA) development with intuitive analytical solutions. Confidently innovate with high-quality, sensitive and accurate data to assess integrity, purity and critical quality attributes (CQAs).
Synthetic oligonucleotide analysis
Work in pursuit of a higher level of quality for characterization of synthetic oligonucleotides—such as single guide RNA (sgRNA) or prime editing guide RNA (pegRNA)—used for CRISPR/Cas9 gene editing applications, along with antisense oligonucleotides (ASOs), small interfering RNA (siRNA) and aptamer therapeutics.